Thrombocytopenia is a common side-effect of cytotoxic chemotherapy and novel targeted agents that can often necessitate the use of platelet transfusions, or result in dose modifications or discontinuation of therapy. Cytotoxic drugs such as alkylating agents are known to induce marrow aplasia, resulting in fewer platelet-generating megakaryocytes and megakaryocyte progenitors with resultant thrombocytopenia. 1 Many newer anti-cancer agents such as proteasome inhibitors and histone deacetylase inhibitors are also known to induce thrombocytopenia, but the effects are of shorter duration and likely a result of a different mechanism than conventional agents. 2, 3 The histone deacetylase inhibitor panobinostat (LBH589) is currently being studied in clinical trials alone, and in combination in multiple myeloma and other hematological malignancies. Synergistic inhibitory effects on tumor cell growth have been reported for panobinostat and several other agents, including the combination of panobinostat and the proteasome inhibitor bortezomib against myeloma cells. 4 In clinical use, panobinostat induces transient thrombocytopenia, with platelet counts returning to normal levels quickly after discontinuation of treatment. 5 We have previously demonstrated that bone marrow (BM) megakaryocyte populations are preserved in mice during and after treatment with bortezomib, allowing for rapid recovery of platelet counts following bortezomib-associated thrombocytopenia. 2 This observation has significant clinical relevance as it allows clinicians to continue to administer bortezomib despite thrombocytopenia based on a different mechanism of action that does not, in fact, cause marrow hypoplasia and megakaryocyte loss, as occurs with conventional agents. The mechanisms of bortezomib-and panobinostat-induced thrombocytopenia are not well understood, but both may involve effects on nuclear factor-kB (NFkB) nuclear translocation and downstream gene targets. [6] [7] [8] Here, we evaluated the kinetics of thrombocytopenia and the fate of BM megakaryocytes in panobinostat-treated mice. We hypothesized that the rate of blood platelet reduction would reflect a panobinostat-induced cessation of platelet production, rather than megakaryocyte loss, and that platelet generation by megakaryocytes would resume on discontinuation of panobinostat treatment. Female BALB/c mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and used for these studies at 12 weeks of age. Experimental procedures were approved by the Emory University Institutional Animal Care and Use Committee. Two groups of 12 mice were injected i.p. at doses of 10 and 20 mg/kg panobinostat (provided by Novartis, Basel, Switzerland) every day for 5 days (Monday-Friday) over a 2-week course. A control group received 5% dextrose in water (D5W vehicle). The average platelet count for untreated mice was 994 Â 10 6 cells/ml. During the first week of panobinostat treatment, platelet counts dropped rapidly (and similarly) in groups receiving 10 or 20 mg/kg, with average day 6 nadir values of 132 and 63 Â 10 6 cells/ml, respectively ( Figure 1a ). The rate of platelet count reduction indicates a half-life of 67 h and is consistent with a decline reflecting normal platelet life span 9 in the absence of new platelet production. This finding suggests that panobinostat halts thrombopoiesis during the treatment phase without direct cytotoxicity to circulating platelets. Platelet counts in the control group remained close to baseline values (Figure 1a) . Platelet counts in panobinostattreated mice partially recovered after the 2-day treatment break, demonstrating that recovery of platelet production occurs very Figure 1 Panobinostat-induced thrombocytopenia in BALB/c mice is rapidly reversed when treatment is stopped, and is inversely correlated with plasma TPO levels. Blood samples were collected through the retro-orbital sinus using EDTA-coated microcapillary tubes. No problems with post-sampling blood loss were observed in control or thrombocytopenic mice. Only three or four mice per group were bled each day, allowing for rest periods. Platelet counts were obtained using an automated hematology analyzer (Beckman Coulter AcT Diff with veterinary software, Brea, CA, USA). Panobinostat dosing (10 rapidly when panobinostat treatment is stopped. Counts then dropped with similar kinetics during the second week of treatments ( Figure 1a) . After a 1-week recovery period, platelet counts rebounded to approximately 50% over the baseline counts. A final measurement on day 31 showed platelet counts similar to untreated control mice ( Figure 1a ). Although splenic platelet counts were not determined, there was no evidence of splenomegaly in LBH589-treated mice killed to obtain BM samples, suggesting that sequestration of platelets in the spleen was not responsible for thrombocytopenia. With regard to effects on other hematopoietic lineages, white blood cells were reduced to approximately 50% of baseline in panobinostat-treated mice during the 2-week treatment phase (data not shown), but also recovered rapidly following cessation of drug treatment. Mice that received 10 and 20 mg/kg panobinostat lost an average of 6 and 12% body weight, respectively, at day 13, and recovered to normal weights by day 31 (data not shown).
To determine whether panobinostat-induced thrombocytopenia was due to loss of the necessary megakaryocytic trophic factors, we also evaluated thrombopoietin (TPO) levels in plasma obtained from the same blood samples used for platelet counts. As with the platelet counts, results for TPO levels in the 10 and 20 mg/kg panobinostat-treated groups were of similar magnitude at each time point. Thus, both groups are combined in the analyses shown in Figure 1b . TPO levels were inversely related to platelet counts: TPO increased as platelet levels dropped and decreased as platelet levels rebounded. TPO levels in the control group also responded, to a lesser extent, to small change in platelet counts, indicating that control of circulating Figure 2 Panobinostat is efficacious against LBRM-33 lymphoma in B10.BR mice, with development of thrombocytopenia in treated animals. Female B10.BR mice, 10-12 weeks old, were injected i.p. with 5 Â 10 6 LBRM-33 cells with stable expression of luciferase. After 2 weeks, the mice were anesthetized and abdominal fur was removed by lotion depilation, bled through the retro-orbital sinus for determination of platelet counts, and injected i.p. with luciferin for bioluminescent imaging according to the manufacturer's instructions (IVIS system and Living Image software, Caliper Life Sciences, Mountain View, CA, USA). After recovery from anesthesia, mice received either i.p. 20 mg/kg panobinostat or D5W (day 1). Dosing was repeated on days 2-5, and days 8-12. Platelet counts and imaging were repeated on days 6 and 13. (a-h) In vivo bioluminescent images, obtained using a 3-min exposure time, from all mice that had detectable tumors (over a threshold of 1 Â 10 5 total photon counts) at one or more time points during the experiment period. The color bar represents the scale used for the pseudocolor image. Four of these mice (a-d) received 20 mg/kg panobinostat and four (e-h) received D5W. (i) Total photon counts were determined for each tumor region on days 1, 6 and 13. Values were log-transformed and averaged for the 20 mg/kg panobinostat or D5W groups. Asterisk (n) indicates P ¼ 0.025 (one-tailed t-test) comparing the change from days 1 to 13 reading for the panobinostat and D5W groups. (j) Average platelet counts on days 1, 6 and 13 from mice that: received D5W but had no detectable tumors (n ¼ 5), received D5W and had detectable tumors (mice e-h), received 20 mg/kg panobinostat but had no detectable tumors (n ¼ 4), or received 20 mg/kg panobinostat and had detectable tumors (mice a-d). Error bars represent the s.e.m.
TPO levels is very sensitive to blood platelet counts (data not shown). These data suggest an absence of an effect of panobinostat on TPO production, and demonstrate that plasma TPO levels reflect continuous TPO production and clearance by binding to circulating platelets. 10 Thrombocytopenia induced by panobinostat was also evaluated in a tumor-bearing mouse model. Female B10.BR mice (n ¼ 17) were injected i.p. with 5 Â 10 6 LBRM-33 T-cell lymphoma cells stably transfected to express a luciferase reporter. At 2 weeks after lymphoma cell administration, the presence of tumors was evaluated using bioluminescent in vivo imaging. Detectable tumors were found in six mice (Figure 2,  day 1) . Three of these (plus five without detectable tumors) received 20 mg/kg panobinostat i.p. using the 5-day schedule for 2 weeks (Figure 1 ). The rest of the mice (three with detectable tumors and six without) received D5W. After the first 5-day treatment cycle (day 6), the bioluminescent signal in the panobinostat-treated tumor-bearing mice was decreased (Figures 2 a-c) , but a new detectable tumor was found in an additional treated mouse (Figure 2d ). After the second cycle (day 13), the signal had reduced in all four of these mice, with one (mouse c) showing no detectable signal. In the D5W group, tumor growth was observed over the 2-week period in the three mice that had detectable tumors at day 1 (Figures 2 e-g ). On dissection, tumor signals were attributed to mesenteric adenopathy or accumulation of tumor cells in the spleen. An additional mouse developed a detectable tumor signal after 1 week, but this was not seen after 2 weeks (mouse h). For further analysis, mice having detectable signal at any time point are considered tumor-bearing mice, and are shown in Figures 2 a-h, whereas mice that never showed detectable tumors are considered nontumor-bearing mice. Because the tumors varied greatly in size and total signal intensity, log-transformed data were used to compare changes in tumor size over time. There was a significant difference in the change (days 1 to 13) in tumor size for the panobinostat-treated (a-d) vs D5W control (e-h) mice (Figure 2i ; P ¼ 0.025), demonstrating efficacy of panobinostat against the LBRM-33 lymphoma in vivo. Platelet counts showed panobinostat-induced thrombocytopenia in both tumor-bearing and nontumor-bearing mice, with a nadir at day 6 (Figure 2j) , similar to the experiment in BALB/c mice. Differences between strains in susceptibility to panobinostatinduced thrombocytopenia may account for reduced severity of thrombocytopenia in B10.BR mice compared with BALB/c, especially at day 13. Mice that received only D5W maintained platelet counts close to baseline measurements, with evidence of some tumor-induced thrombocytopenia in mice with extensive tumor growth.
To study effects of panobinostat on megakaryocyte quantity and differentiation, 2-3 BALB/c mice from the groups shown in Figure 1 were killed at days 6, 13, 19 and 31 to obtain femurs for histological and flow cytometric analysis of BM megakaryocytes. One femur from each mouse was prepared for histology, and morphological and numerical assessments were performed by a pathologist blinded to treatment conditions (DLJ) (Figure 3a) . The overall cellularity for all specimens analyzed (c) Megakaryocyte ploidy distribution in panobinostat-treated mice. Bone marrow cell suspensions were fixed in 70% ethanol, an anti-CD41 (FITC) antibody (BD Pharmingen, San Jose, CA, USA) was used to identify megakaryocytes and 7-AAD staining was used to determine DNA content. Multiparametric flow cytometry was performed using a Becton Dickinson (San Jose, CA, USA) FACSCanto instrument. Events were captured for all cells with DNA content 2N and greater and digital FCS files were analyzed for determinations of megakaryocyte content and ploidy distribution using FlowJo software (Tree Star, Inc., Ashland, OR, USA). The percentage of megakaryocytes, defined as CD41 þ cells, is shown, as well as the fraction of megakaryocytes in each ploidy category.
nnn P ¼ 0.0004, nn P ¼ 0.0052, comparing the percentages of megakaryocytes in marrow at days 6 and 13 compared with controls. n P ¼ 0.0035, comparing the frequency of 2N/4N megakaryocytes at day 6 with controls.
Letters to the Editor was 495%. The average number of megakaryocytes for the control group was 21-24 per two high-power fields, consistent throughout the experiment (Figure 3b ). For each time point, the megakaryocyte count for groups receiving 10 or 20 mg/kg panobinostat were very similar, and were combined in the analyses. At day 6, the average count was 38 per two high-power fields, significantly increased compared with controls (Figure 3b ). For these specimens, 25-33% of the megakaryocytes were smaller than usual with hypolobated nuclei, consistent with immature forms (Figure 3a) . At all subsequent time points, the megakaryocytes were present in normal quantity, with normal cytological appearance (Figures 3 a and b) . Using the remaining femur from each mouse, we identified the CD41 þ megakaryocyte fraction in BM and studied megakaryocyte ploidy by flow cytometric analysis of DNA content. The intensity of 7-AAD DNA staining was used to determine the fraction of megakaryocytes in each ploidy category, 2N, 4N,  8N, 16N, 32N and 64N. Averages were calculated for D5W controls, and for the 10 and 20 mg/kg LBH589 groups combined. In control mice, megakaryocytes made up 0.12% of the collected BM cells (Figure 3c ), consistent with numbers in other reports. 11 Grouping the ploidy values into three categories, 2N/4N cells represented 30% of megakaryocytes, 8N/16N cells made up the largest category at 59 and 11% were 32N/64N cells. The percentage of megakaryocytes in the BM was significantly increased in panobinostat-treated mice at days 6 and 13, and the day 6 representation of 2N/4N cells among CD41 þ cells was significantly increased to 37% (Figure 3c ). The differences in the results from histological assessment and flow cytometry studies are likely due to technical differences in megakaryocyte quantification using these methods. However, both methods indicate increased numbers of megakaryocytes, especially smaller immature forms, at day 6 in panobinostat-treated mice, followed by a return to normal megakaryocyte levels by day 19. This finding is also consistent with a model of thrombocytopenia involving temporary disruption of nuclear factor-kB signaling, as the NFkB transcription factor is important in megakaryocyte maturation, 8 and panobinostat is known to block nuclear translocation of NFkB. 6 A study by Matsuoka et al. 12 also found that megakaryocyte numbers in rat spleen increase in response to the histone deacetylase inhibitor FR235225, and that inhibition of GATA-1 in megakaryocytes is associated with histone deacetylase inhibitor-induced thrombocytopenia. Thus, our data show that megakaryocytes are neither lost nor undergo prolonged morphological changes because of therapy, and that enhanced megakaryocytopoiesis ensues following induction of thrombocytopenia.
Our study of panobinostat exposure in mice confirms clinical observations that panobinostat-induced thrombocytopenia is transient and that platelet counts recover rapidly after treatment is stopped. The rate of platelet decrease interpreted in light of the lack of megakaryocyte loss is consistent with a temporary inability of megakaryocytes to produce new platelets. Recovery involves a rebound effect with increased megakaryocyte generation and temporarily elevated megakaryocyte numbers in the BM for rapid thrombopoiesis. These findings suggest, similar to our earlier work with bortezomib, 2 that the ability of megakaryocytes to rapidly restore platelet levels following panobinostat exposure should be taken into consideration in determining treatment regimens for patients receiving panobinostat as therapy for myeloma and other malignancies.
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